Halozyme Therapeutics (HALO) Total Non-Current Liabilities (2012 - 2026)

Halozyme Therapeutics (HALO) has 15 years of Total Non-Current Liabilities data on file, last reported at $2.3 billion in Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities rose 41.55% year-over-year to $2.3 billion in Q1 2026; TTM through Mar 2026 was $2.3 billion, a 41.55% increase from a year earlier, with the FY2025 full-year figure at $2.4 billion, up 43.63% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $2.3 billion, down from $2.4 billion in the prior quarter.
• Over the last five years, Total Non-Current Liabilities for HALO reached as high as $2.4 billion in Q4 2025 and fell as low as $1.2 billion in Q1 2022.
• Historically, Total Non-Current Liabilities has averaged $1.7 billion across 5 years, with a median of $1.6 billion in 2024.
• Across the five-year window, Total Non-Current Liabilities surged 61.33% in 2022 and retreated 13.13% in 2023, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $1.7 billion in 2022, then declined by 2.69% to $1.6 billion in 2023, then increased by 2.06% to $1.6 billion in 2024, then jumped by 43.63% to $2.4 billion in 2025, then decreased by 0.68% to $2.3 billion in 2026.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $2.3 billion in Q1 2026, $2.4 billion in Q4 2025, and $1.6 billion in Q3 2025.